LY-215,840

LY-215,840 is a drug that was developed by Eli Lilly and is a serotonin 5-HT2A and 5-HT2C receptor antagonist. It has been researched for potential use in the treatment of schizophrenia and anxiety disorders, but was not pursued for further development and is not currently marketed.

History

LY-215,840 was first synthesized by researchers at Eli Lilly in the late 20th century. It was part of a series of compounds designed to target the 5-HT2A and 5-HT2C receptors, which are known to be involved in the regulation of mood and anxiety.

Pharmacology

LY-215,840 acts as an antagonist at the 5-HT2A and 5-HT2C receptors. This means it blocks the action of serotonin at these receptors, which can have various effects on the body. In particular, it has been suggested that this could be beneficial in the treatment of conditions such as schizophrenia and anxiety disorders.

Clinical trials

Although LY-215,840 showed promise in early preclinical studies, it was not pursued for further development. This was due to a variety of factors, including the complexity of the serotonin system and the difficulty in predicting the clinical effects of manipulating this system.

See also

• 5-HT2A receptor
• 5-HT2C receptor
• Eli Lilly
• Schizophrenia
• Anxiety disorder

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia